首页> 外文期刊>Die Pharmazie >Relationship between the administration of nicardipine hydrochloride and the development of delirium in patients on mechanical ventilation
【24h】

Relationship between the administration of nicardipine hydrochloride and the development of delirium in patients on mechanical ventilation

机译:Nicardipine 盐酸钠施用与机械通气患者谵妄的关系

获取原文
获取原文并翻译 | 示例
       

摘要

A history of hypertension is a known risk factor for delirium in patients in intensive care units, but the effect of antihypertensive agents on delirium development is unclear. Nicardipine, a calcium channel blocker, is widely used in ICU as a treatment agent for hypertensive emergency. This study investigated the relationship between the administration of nicardipine hydrochloride and delirium development in patients under mechanical ventilation. We conducted a medical chart review of 103 patients, who were divided into two groups according to the use of nicardipine hydrochloride. The prevalence of delirium was compared with respect to factors such as age, sex, laboratory data, and medical history, by multivariate analysis. 21 patients (20.4 %) were treated with nicardipine hydrochloride in 103 patients. The treatment and non-treatment groups differed significantly in age (72 vs. 65 years) and history of high blood pressure (57% vs. 11%). Multivariate analysis revealed that patients in the treatment group developed delirium significantly less often than those in the non-treatment group (19% vs. 48%). These results suggested that treatment of high blood pressure with nicardipine hydrochloride is a possible method for preventing the development of delirium.
机译:高血压病史是一种已知的患者在重症监护单位的患者中的危险因素,但抗高血压药物对谵妄发展的影响尚不清楚。 Nicardipine是一种钙通道阻滞剂,广泛用于ICU作为高血压紧急治疗剂的治疗剂。本研究研究了机械通气患者盐酸尼卡宁盐酸盐和谵妄发育之间的关系。我们对103名患者进行了医学图表审查,根据使用Nicardipine盐酸盐分为两组。通过多变量分析,与年龄,性别,实验室数据和病史等因素相比,谵妄的患病率进行了比较。在103名患者中,用Nicardipine盐酸盐处理21例(20.4%)。治疗和非治疗组在年龄(72针对65岁)和高血压史(57%vs.11%)不同。多变量分析显示,治疗组的患者显着不如非治疗组(19%vs.48%)显着较低的谵妄。这些结果表明,用盐酸尼卡丁治疗高血压是防止谵妄发展的可能方法。

著录项

  • 来源
    《Die Pharmazie》 |2018年第12期|共4页
  • 作者单位

    Tokushima Univ Dept Clin Pharmacol &

    Therapeut Inst Biomed Sci Grad Sch Tokushima Japan;

    Okayama Univ Dept Emergency Pharmaceut Sci Grad Sch Med Dent &

    Pharmaceut Sci Okayama Japan;

    Tokushima Univ Dept Clin Pharmacol &

    Therapeut Inst Biomed Sci Grad Sch Tokushima Japan;

    Tokushima Univ Hosp Clin Trial Ctr Dev Therapeut 2-50-1 Kuramoto Cho Tokushima 7708503 Japan;

    Nihon Univ Itabashi Hosp Dept Pharm Tokyo Japan;

    Tokushima Univ Dept Clin Pharmacol &

    Therapeut Inst Biomed Sci Grad Sch Tokushima Japan;

    Okayama Univ Dept Clin Pharm Grad Sch Med Dent &

    Pharmaceut Sci Okayama Japan;

    Tokushima Univ Hosp Dept Pharm Tokushima Japan;

    Tokushima Univ Hosp Dept Pharm Tokushima Japan;

    Tokushima Univ Hosp Dept Pharm Tokushima Japan;

    Tokushima Univ Hosp Dept Pharm Tokushima Japan;

    Tokushima Univ Hosp Dept Pharm Tokushima Japan;

    Tokushima Univ Hosp Clin Trial Ctr Dev Therapeut 2-50-1 Kuramoto Cho Tokushima 7708503 Japan;

    Tokushima Univ Dept Pharmacol Inst Biomed Sci Grad Sch Tokushima Japan;

    Beth Israel Deaconess Med Ctr Dept Surg Harvard Med Sch Boston MA USA;

    Tokushima Univ Hosp Clin Trial Ctr Dev Therapeut 2-50-1 Kuramoto Cho Tokushima 7708503 Japan;

    Okayama Univ Hosp Dept Hosp Pharm Okayama Japan;

    Okayama Univ Hosp Dept Hosp Pharm Okayama Japan;

    Okayama Univ Dept Emergency &

    Crit Care Med Grad Sch Med Dent &

    Pharmaceut Sci Okayama Japan;

    Tokushima Univ Dept Clin Pharmacol &

    Therapeut Inst Biomed Sci Grad Sch Tokushima Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

  • 入库时间 2022-08-20 08:21:43

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号